| 2/23 | A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis. (opens in a new tab) Journal of Crohn's and Colitis, Volume 17, Issue Supplement 1. (Publication P577). February 2023.
|
|---|
| 10/21 | Safety and Tolerability of NX-13 in a Randomized, Double-Blind Placebo Controlled Phase I Study in Normal Healthy Volunteers. (opens in a new tab) Safety and Tolerability of NX-13 in a Randomized, Double-Blind Placebo Controlled Phase I Study in Normal Healthy Volunteers. (Publication P0480). October 2021.
|
|---|
| 11/19 | Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. (opens in a new tab) The Journal of Immunology. November 6, 2019.
|
|---|
| 6/19 | Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1. (opens in a new tab) Drug and Chemical Toxicology . June 10, 2019 .
|
|---|
| 5/19 | Su1818 – Preclinical Efficacy and Safety of Nx-13: A Novel Nlrx1-Targeting Immunometabolic Therapeutic for Crohn’s Disease and Ulcerative Colitis. (opens in a new tab) AGA Journals . May 2019.
|
|---|
| 2/18 | NLRX1 Modulates Immunometabolic Mechanisms Controlling the Host-Gut Microbiota Interactions during Inflammatory Bowel. (opens in a new tab) Disease Front Immunol. February 2018.
|
|---|
| 3/17 | NLRX1 Regulates Effector and Metabolic Functions of CD4+ T Cells. (opens in a new tab) J Immunol. March 2017.
|
|---|
